What you might want to know:

– CancerIQ, a Chicago, IL-based precision well being platform centered on empowering healthcare suppliers to personalize most cancers prevention and early detection, introduced it has secured a progress financing bundle from Decathlon Capital Companions.

– Whereas particular monetary particulars of the transaction weren’t disclosed, the funding will allow CancerIQ to additional develop its digital instruments, introduce new choices and strengthen partnerships with healthcare suppliers throughout the nation.

Customized most cancers detection

CancerIQ strives to stay on the forefront of precision well being expertise. The corporate’s concentrate on steady innovation ensures that healthcare suppliers have entry to probably the most superior instruments to establish most cancers threat, information genetic testing, and enhance affected person adherence to personalised care plans.

CancerIQ’s platform is designed to combine seamlessly into digital well being document (EHR) workflows, making it a useful instrument for healthcare suppliers throughout a wide range of medical settings. The platform empowers healthcare suppliers to precisely establish sufferers’ lifetime and hereditary most cancers dangers. With this info, healthcare suppliers can ship personalised most cancers prevention methods and early detection plans tailor-made to every affected person’s distinctive threat profile.

One of many key options of CancerIQ’s platform is its user-friendly interface, making it accessible to suppliers no matter their technical experience. The platform makes use of up-to-date medical pointers to make sure that genetic testing and personalised care plans are based mostly on the newest medical proof. This strategy not solely improves the uptake of genetic testing, but in addition improves affected person outcomes by selling adherence to personalised most cancers care plans.

“The CancerIQ platform is designed to assist healthcare suppliers be sure that each affected person receives the care they should handle their particular person most cancers threat — from prevention and early detection to therapy and survivorship,” Ayodele stated. “It’s time to maneuver past the one-size-fits-all strategy to most cancers prevention and guarantee individuals get the care they should keep forward of most cancers,” stated Feyi Olopade Ayodele, co-founder and CEO of CancerIQ.